# Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF

> **NCT05077683** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 560 (actual)

## Conditions studied

- Myocardial Infarction, Acute
- Left Ventricular Thrombus

## Interventions

- **DRUG:** Rivaroxaban 2.5 MG [Xarelto]
- **DRUG:** DAPT strategy

## Key facts

- **NCT ID:** NCT05077683
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-10
- **Primary completion:** 2023-03-10
- **Final completion:** 2024-02-09
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077683, "Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05077683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*